Rhenman & Partners Asset Management’s Charles River Laboratories CRL Stock Holding History

Rhenman & Partners Asset Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.49M	Buy	26,000 +4,000	+18%	+$742K	0.55%	59
2025 Q4	$4.39M	Buy	+22,000	New	+$3.99M	0.41%	66
2025 Q1	–	Sell	-14,850	Closed	-$2.74M	–	96
2024 Q4	$2.74M	Sell	14,850 -22,650	-60%	-$4.36M	0.28%	72
2024 Q3	$7.39M	Buy	37,500 +3,500	+10%	+$727K	0.6%	54
2024 Q2	$7.02M	Buy	34,000 +21,300	+168%	+$4.83M	0.67%	43
2024 Q1	$3.44M	Sell	12,700 -25,300	-67%	-$6.04M	0.33%	61
2023 Q4	$8.98M	Sell	38,000 -6,000	-14%	-$1.18M	0.9%	42
2023 Q3	$8.62M	Buy	+44,000	New	+$9.03M	0.93%	37

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Rhenman & Partners Asset Management's CRL Position: Q1 2026 in Review

Rhenman & Partners Asset Management increased its Charles River Laboratories (CRL) stake by 18% in Q1 2026, buying an estimated $742K and bringing the position to 26,000 shares worth $4.49M. The position accounts for 0.55% of the portfolio, ranked #59.

Rhenman & Partners Asset Management first reported a position in CRL in Q3 2023 and has held it in 8 quarters since. The position peaked at $8.98M in Q4 2023. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

Rhenman & Partners Asset Management held 26,000 shares of Charles River Laboratories worth $4.49M as of Q1 2026.
Rhenman & Partners Asset Management bought 4,000 Charles River Laboratories shares in Q1 2026, an estimated $742K.
Charles River Laboratories made up 0.55% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #59 holding.
Rhenman & Partners Asset Management first reported a position in Charles River Laboratories in Q3 2023 and has held it in 8 quarters since.
Rhenman & Partners Asset Management's Charles River Laboratories position peaked at $8.98M in Q4 2023.
557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.